Mural Oncology (NASDAQ:MURA) Cut to Outperform at Raymond James

Raymond James lowered shares of Mural Oncology (NASDAQ:MURA) from a strong-buy rating to an outperform rating in a report issued on Tuesday, MarketBeat Ratings reports. They currently have $18.00 target price on the stock.

MURA has been the topic of a number of other research reports. Jones Trading reissued a “hold” rating on shares of Mural Oncology in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Mural Oncology in a research note on Wednesday, March 12th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

Mural Oncology Stock Up 1.5 %

Shares of NASDAQ MURA opened at $1.35 on Tuesday. The stock has a market capitalization of $23.26 million, a price-to-earnings ratio of -0.15 and a beta of 3.66. Mural Oncology has a 52 week low of $1.28 and a 52 week high of $5.12. The firm has a 50-day simple moving average of $3.77 and a 200-day simple moving average of $3.58.

Mural Oncology (NASDAQ:MURA) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter in the prior year, the business posted ($3.57) EPS. As a group, equities research analysts expect that Mural Oncology will post -7.54 EPS for the current year.

Hedge Funds Weigh In On Mural Oncology

Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in shares of Mural Oncology by 2.6% during the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after buying an additional 4,731 shares during the period. FMR LLC grew its holdings in Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after acquiring an additional 11,423 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Mural Oncology in the 3rd quarter valued at approximately $340,000. Commerce Bank acquired a new stake in shares of Mural Oncology in the 3rd quarter valued at $39,000. Finally, Jane Street Group LLC purchased a new stake in shares of Mural Oncology during the 4th quarter worth $68,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.